INTRODUCTION AND OBJECTIVES: According to data from SEER (http://seer.cancer.gov/) in the United States, bladder cancer (BC) has improved 5-year survival rate by only 3% in the last two decades. D-3-phosphoglycerate dehydrogenase (PHGDH) is an enzyme that converts 3-phosphoglycerate on glycolysis system and induces metabolism to serine synthesis. Cancers require serine to maintain rapid, sustained and uncontrollable proliferation. Recently it has been reported that PHGDH can be a therapeutic target in breast cancer and melanoma, on the other hand there has been no report on BC. The aim of this study is to evaluate therapeutic possibility regarding PHGDH in BC.
METHODS: Clinical significance of PHGDH in BC was analyzed using The Cancer Genome Atlas (TCGA) which is a public database. In addition, the effect of PHGDH inhibitor (NCT-503) and si-RNA against PHGDH was evaluated by cell proliferation and apoptosis assay in BC cell lines (T24, BOY, KK47, UMUC-3, J82). In xenograft assay, PHGDH knockdown efficiency was investigated using sh-RNA against PHGDH. Furthermore, additive effect of the PHGDH inhibitor under Gemcitabine and Cisplatin (GC) administration was examined.
RESULTS: In the PHGDH high expression group (n [ 157), the prognosis was poor (P [ 0.0032) compared with the low expression group (n [ 247), and PHGDH was found to be an independent poor prognostic factor (P [ 0.001) in multivariate analysis. The PHGDH inhibitor and PHGDH si-RNAs significantly inhibited proliferative ability through induction of apoptosis (P < 0.05) in BC cell lines. Western blot analyses showed that Ki-67 expression was markedly repressed and cleaved caspase-3 expression was increased in PHGDH knockdown BC cells compared with those in control BC cells. Additionally, cells with PHGDH overexpression promoted tumor cell viability in comparison to control cells. In xenograft assay, PHGDH knockdown by sh-RNA significantly inhibited tumor progression compared to the vehicle group (P < 0.05). Furthermore, the combination treatment between PHGDH inhibitor and GC showed synergistic tumor suppressive effect compared to each single agent group (P < 0.05) in proliferation assay.
CONCLUSIONS: Our study revealed that PHGDH inhibition showed tumor suppressive effects in BC. Furthermore, the combination therapy between PHGDH inhibitor and GC showed synergistic effect in proliferation assay. Novel therapeutic implications through functional analysis of PHGDH in BC were suggested. protein lysine methyltransferase, has a key role in activating of many oncogenes transcription in a variety of cancers. The carcinogenic mechanism of SMYD3 is rarely studied in bladder cancer (BCa). Here, we investigated the role of SMYD3 in regulating autophagy and the antitumor effect by inhibiting SMYD3 in BCa cells.
METHODS: Oncomine database and tissue microarray were used to investigate the expression of SMYD3 in clinical BCa specimens. Small interfering RNA (siRNA) was used to knockdown SMYD3 expression. We studied the relationship between autophagic flux and apoptosis using confocal microscopy, flow cytometry, western blot and cck-8 assay. Western blot assay and confocal microscopy were used to investigate SMYD3 regulated autophagy. The xenograft transplantation, animal imaging technology, immumohistochemistry (IHC) were used to test the anti-tumor effect of targeting SMYD3 In vivo.
RESULTS: Oncomine database and TMA results showed a significant correlation between upregulated SMYD3 expression and poor overall survival. For BCa patients, SMYD3 was positively corelated with gender (p[0.018), T stage (p[0. 029) and tumor grade (p[0. 001). SMYD3 could inhibit protective autophagy by activating mTOR signaling pathway in BCa cells, and this kind of autophagy had balance relationship with apoptosis which was induced by autophagy inhibitor 3-methyladenine (3-MA). The combined administration of SMYD3 inhibitor EPZ031686 and 3-MA could inhibit mTOR signaling pathway synergically and show a dramatic anti-tumor effect.
CONCLUSIONS: SMYD3 has a potential to be a biomarker of invasive bladder cancer. Combined inhibition of SMYD3 and autophagy might be a treatment strategy for bladder cancer. Here we sought to confirm the expression pattern of transgelin and figure out its exact function and mechanism in bladder cancer.
METHODS: Total 137 paired (primary bladder cancer and adjacent non-malignant tissue) and 219 cancer paraffin specimens and 27 paired fresh specimens were obtained from Peking University First Hospital. The expression level of transgelin in bladder cancer was detected by qRT-PCR and immunohistochemistry and validated by online datasets. After the construction of transgelin overexpression and knockdown cell lines, cell proliferation, colony formation, migration, invasion, and invadopodia formation were assayed in vitro. While in vivo tumor metastasis was evaluated by intravenously injecting bladder cancer cells into nude mice. Downstream targets of transgelin were investigated by qRT-PCR, western blot and bioinformatics analysis of online datasets.
RESULTS: Transgelin was highly expressed in bladder cancer and correlated with advanced tumor stage, lymphatic metastasis, and poor prognosis. Inhibition of transgelin repressed cell colony formation, migration, invasion and invadopodia formation in vitro. Inhibition also led to a decrease in the number and size of lung metastases in vivo. Meanwhile, overexpression of transgelin displayed the relevant Vol. 201, No. 4S, Supplement, Sunday, May 5, 2019 THE JOURNAL OF UROLOGY Ò e725
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